PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1461419
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1461419
The global vascular embolization market is estimated to be valued at USD 1,932.9 Mn in 2024 and is expected to exhibit a CAGR of 9.5% during the forecast period (2024-2031).
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2023/2024: | US$ 1,932.9 Mn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 9.50% | 2030/2031 Value Projection: | US$ 3,648.2 Mn |
Vascular embolization refers to the passage and lodging of an embolus within the bloodstream. It is a minimally invasive treatment that blocks one or more blood vessels or abnormal vascular channels. Vascular embolization agents are used to acutely stop flow in blood vessel or vascular area by the means of mechanical occlusion. These agents are released into the blood through a catheter to biologically or mechanically occlude the target vessel; permanently or temporarily. High success rate, rare use of anesthetics, faster recovery time, minimal risk of infection, and no scarring are some features of vascular embolization agents. Embolization is a common and effective procedure in interventional radiology. It is an alternative to open surgery.
Increasing number of clinical trials and increase in research and development is expected to augment the growth of the global vascular embolization market during the forecast period. For instance, in March 2021, Instylla Inc. reported the enrollment of the first patients in the pivotal Embrace Hydrogel Embolic System (HES) global randomized clinical trial for the treatment of hypervascular tumors.
In March 2022, Instylla announced the publication of results from the first-in-human clinical trial of Embrace Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR). The study demonstrated that HES effectively embolized malignant & benign hypervascular tumors by blocking tumor blood supply with technical success and persistent embolization, as noted in imaging follow-up at 30-days, in all eight patients treated on this study.